Making cancer care smart with Oncotype IQ genomic tests
Improve outcomes by optimizing cancer care treatment and monitoring
LEARN MORE
Lloyd, an Oncotype DX patient
VIEW EVENTS

ASCO Guidelines

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients

AUA 2022

May 12-16th, 2022 in New Orleans, LA

Visit us at booth 647 for exclusive access to the 2022 Guidelines at a Glance Prostate Cancer Edition.
Improving Patient Outcomes

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™